ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
Maruti Suzuki Q1 profit drops 11% to Rs 3,352 crore amid rising input costs
Maruti Suzuki reported an eleven percent profit decline in the June quarter. Rising input costs, aggravated by West Asia hostilities, impacted profitability significantly. However, net